One of the performances of synthesized pharmaceutical compounds can be highlighted as following: estrogen receptors (ER) and aromatase enzymes are two important factors in cancer therapy, more precisely in breast cancer; hormone therapy can inhibit estrogen production by blocking aromatase or using ligands to block estrogen receptors and stopping estrogen activity and cell growth [85]. This evidence concerns the gene CYP19A1 and cancer.